Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 2Breast 2Head & Neck 1Genitourinary 1

Conditions

Prostatic Neoplasms 5Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Kidney Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Breast Neoplasms, Male 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Docetaxel 35pembrolizumab 32Nivolumab 27enzalutamide 20Prednisone 20Sunitinib 16Cyclophosphamide 16aldesleukin 14Zoledronic Acid 13Interleukin-2 13Gemcitabine 13Bevacizumab 13Specimen Handling 12Ipilimumab 12Radiosurgery 11Everolimus 11Androgen Antagonists 11Abiraterone Acetate 11fludarabine 10Sorafenib 10Radiotherapy 10Paclitaxel 10Magnetic Resonance Spectroscopy 10pazopanib 9abiraterone 9Doxorubicin 8Carboplatin 8Biopsy 8avelumab 7temsirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × vandetanib × Genitourinary × Clear all
NCT00498797 2016-10-07

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Sanofi

Phase 2 Completed
86 enrolled 8 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡